bioecon Member area
Technology · Health & biomedicine / Diagnostics & medtech

Personalized diagnostics

Molecular diagnostics leveraging NGS, liquid biopsy, and AI for precision medicine and targeted therapies.

Risk: low Diagnostics US · CN · EU Science: why it works → verified 2026-06-25 · 6 Sources (0 independent)

1 · What it gives

Personalized diagnostics represents the foundation of precision medicine, utilizing advanced genomic and molecular tools to tailor medical treatment to individual patient profiles. By shifting from a “one-size-fits-all” approach to individualized therapies, the sector focuses heavily on Next-Generation Sequencing (NGS), liquid biopsy, and companion diagnostics. Utilizing circulating tumor DNA (ctDNA) from non-invasive blood draws, these technologies enable multi-cancer early detection and minimal residual disease (MRD) monitoring, fundamentally altering oncology care. The global NGS diagnostic market, valued at $3.8 billion, exhibits a 28% year-over-year growth, driven by falling sequencing costs and expanding clinical coverage.

The key directions of personalized diagnostics are:

  1. NGS Oncology Diagnostics: Comprehensive Genomic Profiling (CGP) using 300–600 gene panels to match tumors with targeted therapies.
  2. Liquid Biopsy: Non-invasive monitoring of circulating tumor DNA (ctDNA) for cancer relapse and early multi-cancer detection (MCED).
  3. Companion Diagnostics (CDx): Specific tests required to determine patient eligibility for corresponding targeted therapeutic drugs.
  4. CRISPR Diagnostics: Fast, point-of-care diagnostic chips identifying viral pathogens and antimicrobial resistance within 30 minutes.

Sectoral value chain#

[Sample Collection] ──> [Nucleic Acid Extraction] ──> [Library Preparation] ──> [Sequencing / Detection]
                                                          │
                                                (Target Enrichment)
                                                          │
                                                          ▼
[Targeted Therapy Selection] <─── [Clinical Reporting] <─── [AI Bioinformatics Analysis]

Value chain levels#

LevelDescriptionKey inputs/outputs
Sample CollectionCollection of blood, tissue, or saliva utilizing stabilized collection tubesIn: Patient biofluid.
Out: Stabilized sample.
ExtractionAutomated isolation of high-quality DNA, RNA, or circulating tumor DNAIn: Stabilized sample.
Out: Purified nucleic acids.
Library PrepFragmentation, adapter ligation, and target enrichment for specific genomic regionsIn: Nucleic acids.
Out: Sequencing libraries.
SequencingHigh-throughput reading of millions of DNA fragments in parallel (NGS)In: Libraries.
Out: Raw genomic data.
BioinformaticsAlignment, variant calling, and mutation annotation using specialized softwareIn: Raw data.
Out: Variant profiles.
Clinical InterpretationMatching genetic variants with clinical databases to guide therapy decisionsIn: Variant profiles.
Out: Actionable medical report.

Cross-cutting technologies of the sector:

  • Next-Generation Sequencing (NGS): Massively parallel sequencing technology driving genomics with exponential cost reductions.
  • Liquid Biopsy: Detection of cell-free DNA (cfDNA) and exosomes in blood to profile tumors without invasive surgery.
  • Artificial Intelligence in Diagnostics: Multimodal models combining genomic, imaging (radiogenomics), and clinical data for predictive oncology.

2 · What it replaces 2 · matched by industry

D2E4Crop disease forecasting models, spore traps, pheromone and smart pest traps and field diagnostics — spray when risk is real instead of calendar-based fungicide and insecticide programmes
Replaces: Fixed-interval ("calendar") protective fungicide sprays and routine insecticide applications regardless of pest pressure
EAC
D2E–On-farm culture, PCR panels, rapid tests and veterinary laboratory services for livestock and aquaculture — treat what is diagnosed instead of blanket and prophylactic antibiotic treatment
Replaces: Blanket treatment of every clinical mastitis case, group metaphylaxis on suspicion, prophylactic antibiotics in hatcheries and ponds, …
DIAG

3 · How to implement 6 steps

  1. 1
    Liquid Biopsy Draw
    A standard peripheral blood sample is collected into specialized tubes containing preservatives that prevent white blood cell lysis, ensuring the circulating cell-free DNA (cfDNA) remains uncontaminated.
  2. 2
    cfDNA ExtractionExtraction
    In a certified laboratory, plasma is separated via centrifugation. Automated robotic liquid handling systems isolate and purify the extremely sparse and fragmented cfDNA using magnetic bead technology.
    Who can do this step matched automatically
    India Glycols (NSE) India
    ✓ GMP 7,500 MT/ industrial scale
    “ Novel technologies, including super critical technology for nutraceuticals where carbon dioxide is used as a green solvent during extraction processes.”
  3. 3
    Targeted Library Prep
    The purified cfDNA undergoes end repair, A-tailing, and adapter ligation. Hybridization capture probes enrich specific oncology-relevant genes (e.g., 300 to 500 gene panels) to focus sequencing power on target regions.
  4. 4
    Massively Parallel Seq
    The prepared libraries are loaded onto high-throughput NGS flow cells. The sequencer performs thousands of cycles, generating millions of short reads with ultra-deep coverage required to detect rare mutations (allele fractions below 0.1%).
  5. 5
    Variant Calling (AI)Data, software & automationTesting & analytics
    Bioinformatics pipelines process the raw sequencing reads. AI-assisted algorithms align the sequences to a reference genome, correct sequencing errors, and identify single nucleotide variants (SNVs), indels, and fusions.
    Who can do this step matched automatically
    Stellapps India
    240,000 liters/day
    “It leverages advanced analytics and artificial intelligence through its full-stack IoT platform to enable dairy ecosystem partnerships with financial & insurance institutions, …”
    India Glycols (NSE) India
    ✓ GMP 7,500 MT/ industrial scale
    “Even the administrative processes are green, where IGL has adopted the latest SAP ERP (S/4 HANA 2023 version), Salesforce CRM, Industrial IOT & other tech solutions to drive …”
    GenScript ProBio / Genscript China
    ✓ GMP industrial scale
    “ProBio: A global CRDMO (contract research, development, and manufacturing organization) providing end-to-end solutions for biologics and cell and gene therapy (CGT).”
    China Everbright Environment Group China
    163,050 tonnes
    “As the fundamental component of 5G deployment, optic fibre is critical to making Hong Kong a smart city and laying the groundwork for IoT.”
    Esco Aster Singapore
    5,000 L industrial scale
    “Esco Aster (Singapore) is a cGMP contract research, development and manufacturing organization (CRDMO/CDMO) and bioinnovation venture accelerator that helps clients and …”
    Ninjacart India
    25,000 tonnes/year
    “Data and SaaS capabilities: Acquired Tecxprt to enhance SaaS-based smart solutions for the agri ecosystem, signaling emphasis on software-driven optimization and digital services.”
  6. 6
    CDx Report Generation
    The detected variants are cross-referenced with curated clinical and pharmacological databases. A final report is generated identifying actionable mutations and recommending specific targeted therapies or clinical trials.

4 · Who delivers

Matched suppliers (matched automatically)

Vaxxinova NorwayNorwayNot classifiedactive
Amano EnzymeJapanProduceractive
CodexisUnited StatesProduceractive
HipraSpainProduceractive
LoopwormIndiaServices / consultingactive
EW GroupGermanyProduceractive

In the services and supply catalogue 3 · paid service

Analytical & testing services · Laboratory & analytical instruments · Reagents & kits

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Illumina🇺🇸 USANovaSeq, DRAGEN75% of global NGS platformsoperating
Guardant Health🇺🇸 USAGuardant360FDA-approved liquid biopsyoperating
BGI Genomics🇨🇳 ChinaDNBSEQLowest cost whole genome sequencingoperating
Burning Rock🇨🇳 ChinaOncoCompassLiquid biopsy and cancer screeningoperating
Qiagen🇩🇪 GermanyQIAstat-DxCompanion diagnostics leaderoperating
Tempus🇺🇸 USATempus xTAI-guided genomic profilingoperating

5 · Rules & route to market

Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

The United States leads the global personalized diagnostics market with the highest number of FDA-approved liquid biopsies and companion diagnostics.

FDA breakthrough devices, Illumina dominance, liquid biopsy pioneers#

  • Sequencing Dominance: American companies like Illumina produce over 75% of global NGS platforms, setting the gold standard.
  • FDA Approvals: Guardant Health secured the first FDA-approved liquid biopsy for non-small cell lung cancer (NSCLC) profiling.
  • Multi-Cancer Early Detection: Companies like Grail launched the Galleri test utilizing cfDNA methylation to screen for over 50 cancer types from a single blood draw.
European Union

The European Union focuses on rigorous clinical validation (IVDR) and continental data sharing initiatives.

IVDR compliance, European Health Data Space, companion diagnostics#

  • Strict Regulation: The IVDR shift demands extensive clinical evidence for diagnostic tests, causing a transition from in-house lab tests to validated commercial platforms.
  • European Health Data Space (EHDS): An initiative uniting electronic health records and genetic data across 27 EU nations to fuel biomarker discovery while respecting GDPR.
  • Companion Diagnostics Integration: European pharma giants require validated CDx platforms, supplied by companies like Qiagen, to prescribe targeted treatments safely.
China

China relies on massive state-backed biobanks and localized sequencing giants to become a strategic center for precision medicine.

Mass sequencing scale, BGI genome cost, NMPA approvals#

  • Lowest Sequencing Costs: BGI Genomics offers the world’s most affordable whole genome sequencing (WGS), driving mass adoption in developing nations.
  • Liquid Biopsy Commercialization: Burning Rock leads oncology NGS in China, submitting liquid biopsy panels for early colorectal cancer screening to the NMPA.
  • Data Sovereignty: Strict genomic data security laws require local analysis, prohibiting the export of Chinese genomic data and fostering a self-sufficient domestic ecosystem.

6 · Money: tenders & grants

TenderGreece – Biochemical analysers – ΗΛΕΚΤΡΟΝΙΚΟΣ ΑΝΟΙΚΤΟΣ ΔΙΑΓΩΝΙΣΜΟΣ ΑΝΩ ΤΩΝ ΟΡΙΩΝ ΣΕ ΕΥΡΩ ΓΙΑ ΤΗΝ ΠΡΟΜΗΘΕΙΑ …
ΓΕΝΙΚΟ ΑΝΤΙΚΑΡΚΙΝΙΚΟ ΟΓΚΟΛΟΓΙΚΟ ΝΟΣΟΚΟΜΕΙΟ ΑΘΗΝΩΝ "Ο ΑΓΙΟΣ ΣΑΒΒΑΣ" · Greece
Dec 11, 2026
56 days
TenderNetherlands – Blood-testing reagents – Gevalideerde Totaaloplossing voor de hielprikscreening op …
Rijksinstituut voor Volksgezondheid en Milieu (RIVM) · Netherlands
Nov 10, 2026
25 days
GrantAdvancing bio-printing of living cells for regenerative medicine
European Commission · EU
Sep 22, 2027
341 days

7 · Tech stack & innovations

The personalized diagnostics stack combines advanced biochemistry with high-performance computing.

  1. Next-Generation Sequencing Platforms:
    • Massive parallel sequencing arrays reading millions of short DNA fragments simultaneously.
    • Reduced the cost of sequencing a whole human genome from millions to under $200.
  2. Liquid Biopsy and Fragmentomics:
    • Detection of circulating tumor DNA (ctDNA) shed by apoptotic tumor cells into the bloodstream.
    • Relies on ultra-deep sequencing and methylation profiling to detect minimal residual disease (MRD).
  3. CRISPR Point-of-Care Diagnostics:
    • Leveraging Cas12 and Cas13 enzymes (e.g., SHERLOCK and DETECTR) for rapid nucleic acid detection.
    • Provides 30-minute diagnostic turnarounds for infectious diseases on low-cost paper or microfluidic chips.

Sources 6 · 0 independent · 6 producer sites

Producers' own sites 6

  1. Illumina producer checked 2026-02-26 · link not kept
  2. Guardant health producer checked 2026-06-11 · link not kept
  3. Bgi producer checked 2026-06-25 · link not kept
  4. Burning rock producer checked 2026-06-25 · link not kept
  5. Qiagen producer checked 2026-06-11 · link not kept
  6. Tempus ai producer checked 2026-06-01 · link not kept